Trials / Unknown
UnknownNCT05734898
NKG2D CAR-NK & r/rAML
NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 3 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NKG2D CAR-NK | Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-04-01
- Completion
- 2024-09-01
- First posted
- 2023-02-21
- Last updated
- 2023-03-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05734898. Inclusion in this directory is not an endorsement.